These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 20637678)

  • 1. Use of botulinim toxin-A for the treatment of overactive bladder symptoms in patients with Parkinsons's disease.
    Kulaksizoglu H; Parman Y
    Parkinsonism Relat Disord; 2010 Sep; 16(8):531-4. PubMed ID: 20637678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Botulinum toxin type A in patients with Parkinson's disease and refractory overactive bladder.
    Giannantoni A; Conte A; Proietti S; Giovannozzi S; Rossi A; Fabbrini G; Porena M; Berardelli A
    J Urol; 2011 Sep; 186(3):960-4. PubMed ID: 21791351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy.
    Giannantoni A; Rossi A; Mearini E; Del Zingaro M; Porena M; Berardelli A
    J Urol; 2009 Oct; 182(4):1453-7. PubMed ID: 19683298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Botulinum A toxin in the treatment of neurogenic detrusor overactivity: a consolidated field of application.
    Giannantoni A; Mearini E; Del Zingaro M; Santaniello F; Porena M
    BJU Int; 2008 Jul; 102 Suppl 1():2-6. PubMed ID: 18665971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial.
    Herschorn S; Gajewski J; Ethans K; Corcos J; Carlson K; Bailly G; Bard R; Valiquette L; Baverstock R; Carr L; Radomski S
    J Urol; 2011 Jun; 185(6):2229-35. PubMed ID: 21497851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of botulinum toxin type a on overactive bladder symptoms in patients with multiple sclerosis: a pilot study.
    Mehnert U; Birzele J; Reuter K; Schurch B
    J Urol; 2010 Sep; 184(3):1011-6. PubMed ID: 20643431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment.
    Mouttalib S; Khan S; Castel-Lacanal E; Guillotreau J; De Boissezon X; Malavaud B; Marque P; Rischmann P; Gamé X
    BJU Int; 2010 Dec; 106(11):1677-80. PubMed ID: 20590550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Intradetrusor injections of botulinum toxin A to treat urinary incontinence due to bladder overactivity during idiopathic Parkinson's disease].
    Atamian A; Sichez PC; Michel F; Bandelier Q; Fall M; Gaillet S; Azoulay JP; Lechevallier E; Karsenty G
    Prog Urol; 2021 Jun; 31(7):430-438. PubMed ID: 33579624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of urinary tract infection after detrusor botulinum toxin A injections for refractory neurogenic detrusor overactivity in patients with no antibiotic treatment.
    Harris MA; Harding C; Fulford S; Whiteway J
    BJU Int; 2011 Apr; 107(7):1165; author reply 1165. PubMed ID: 21438980
    [No Abstract]   [Full Text] [Related]  

  • 10. Outcomes of intradetrusor onabotulinum toxin A injection in patients with Parkinson's disease.
    Vurture G; Peyronnet B; Feigin A; Biagioni MC; Gilbert R; Rosenblum N; Frucht S; Di Rocco A; Nitti VW; Brucker BM
    Neurourol Urodyn; 2018 Nov; 37(8):2669-2677. PubMed ID: 29767449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum toxin type A for the treatment of gastroparesis in Parkinson's disease patients.
    Gil RA; Hwynn N; Fabian T; Joseph S; Fernandez HH
    Parkinsonism Relat Disord; 2011 May; 17(4):285-7. PubMed ID: 21296606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Best treatment for overactive bladder if behavioral treatment and anticholinergics fail. Onabotulinumtoxina.
    Doggweiler R
    J Urol; 2011 Jun; 185(6):2023-4. PubMed ID: 21496846
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis.
    Khan S; Game X; Kalsi V; Gonzales G; Panicker J; Elneil S; Apostolidis A; Hamid R; Dasgupta P; Kessler TM; Fowler CJ
    J Urol; 2011 Apr; 185(4):1344-9. PubMed ID: 21334639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy.
    Smits MA; Oerlemans D; Marcelissen TA; Van Kerrebroeck PE; De Wachter SG
    J Urol; 2013 Dec; 190(6):2148-52. PubMed ID: 23872028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overactive bladder syndrome - management and treatment options.
    Arnold J; McLeod N; Thani-Gasalam R; Rashid P
    Aust Fam Physician; 2012 Nov; 41(11):878-83. PubMed ID: 23145420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Onabotulinum toxin A: a therapeutic option for refractory neurogenic detrusor overactivity and idiopathic overactive bladder.
    Ellsworth P; Travis M
    Urol Nurs; 2014; 34(4):165-71. PubMed ID: 25233617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder.
    Flynn MK; Amundsen CL; Perevich M; Liu F; Webster GD
    J Urol; 2009 Jun; 181(6):2608-15. PubMed ID: 19375091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Botulinum toxin A for the Treatment of Overactive Bladder.
    Hsieh PF; Chiu HC; Chen KC; Chang CH; Chou EC
    Toxins (Basel); 2016 Feb; 8(3):. PubMed ID: 26938559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Injection of botulinum toxin (BTX-A) in children with bladder dysfunction due to detrusor overactivity].
    Romero RM; Rivas S; Parente A; Fanjul M; Angulo JM
    Actas Urol Esp; 2011 Feb; 35(2):89-92. PubMed ID: 21256633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Onabotulinum toxin A for the treatment of neurogenic detrusor overactivity due to spinal cord injury or multiple sclerosis.
    Goessaert AS; Everaert KC
    Expert Rev Neurother; 2012 Jul; 12(7):763-75. PubMed ID: 22853784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.